FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy

European Journal of Heart Failure

Volumn 14, Issue 5, 2012, Pages 549-562

  Zhang, Yuan ^a   Edgley, Amanda J ^a   Cox, Alison J ^a   Powell, Andrew K ^b   Wang, Bing ^b   Kompa, Andrew R ^b   Stapleton, David I ^c   Zammit, Steven C ^c   Williams, Spencer J ^c   Krum, Henry ^b   Gilbert, Richard E ^d   Kelly, Darren J ^a,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e Fibrotech Therapeutics Pty Ltd   (Australia)

Author keywords

Anti fibrotic therapy; Cardiac fibrosis; Diabetes; Diabetic cardiomyopathy

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; DYE; EOSIN; FT 011; HEMATOXYLIN; PICROSIRIUS RED; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART PRELOAD; HEART STROKE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; MACROPHAGE; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; STAINING;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; CAFFEIC ACIDS; CARDIAC CATHETERIZATION; CARDIOMEGALY; CHRONIC DISEASE; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; FIBROSIS; HEART FAILURE; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; ORTHO-AMINOBENZOATES; RATS; RATS, INBRED STRAINS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 84860384900     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs011     Document Type: Article

References (49)

1. Najafi F, Jamrozik K, Dobson AJ. Understanding the 'epidemic of heart failure': a systematic review of trends in determinants of heart failure. Eur J Heart Fail 2009; 11:472-479.
2. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34.
3. Fang ZY, Najos-Valencia O, Leano R, Marwick TH. Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine. J Am Coll Cardiol 2003;42:446-453.
4. Fischer VW, Barner HB, Larose LS. Pathomorphologic aspects of muscular tissue in diabetes mellitus. Hum Pathol 1984;15:1127-1136.
5. Shimizu M, Umeda K, Sugihara N, Yoshio H, Ino H, Takeda R, Okada Y, Nakanishi I. Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol 1993;46:32-36.
6. Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 2001;87:320-323.
7. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P. Myocardial cell death in human diabetes. Circ Res 2000;87:1123-1132.
8. Kawaguchi M, Techigawara M, Ishihata T, Asakura T, Saito F, Maehara K, Maruyama Y. A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Heart Vessels 1997;12:267-274.
9. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, Haider B. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977;60:884-899.
10. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595-602.
11. Nunoda S, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1985;1:43-47.
12. Border WA, Noble NA. Fibrosis linked to TGF-beta in yet another disease. J Clin Invest 1995;96:655-656.
13. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004;25:543-567.
14. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015-8020.
15. Yamada H, Ide A, Sugiura M, Tajima S. Treatment of cutaneous sarcoidosis with tranilast. J Dermatol 1995;22:149-152.
16. Kelly DJ, Zhang Y, Connelly K, Cox AJ, Martin J, Krum H, Gilbert RE. Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2007;293:H2860-H2869.
17. Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, Krum H, Wilkinson-Berka J, Gilbert RE. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res 2005;65:694-701.
18. Mifsud S, Kelly DJ, Qi W, Zhang Y, Pollock CA, Wilkinson-Berka JL, Gilbert RE. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003;95:p83-p91.
19. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, Fischman D, Goldberg S, Brinker JA, Zeiher AM, Shapiro LM, Willerson J, Davis BR, Ferguson JJ, Popma J, King SB 3rd, Lincoff AM, Tcheng JE, Chan R, Granett JR, Poland M. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002;106:1243-1250.
20. Zammit SC, Cox AJ, Gow RM, Zhang Y, Gilbert RE, Krum H, Kelly DJ, Williams SJ. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorg Med Chem Lett 2009;19:7003-7006.
21. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, Thai K, Feneley MP, Tsoporis J, White KE, Krum H, Gilbert RE. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 2007;76:280-291.
22. Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J 2003;17:1576-1578.
23. Pfeffer JM, Pfeffer MA, Frohlich ED. Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med 1971;78:957-962.
24. Georgakopoulos D, Kass DA. Estimation of parallel conductance by dualfrequency conductance catheter in mice. Am J Physiol Heart Circ Physiol 2000; 279:H443-H450.
25. Yang B, Larson DF, Beischel J, Kelly R, Shi J,Watson RR. Validation of conductance catheter system for quantification of murine pressure-volume loops. J Invest Surg 2001;14:341-355.
26. Weiss JL, Frederiksen JW,Weisfeldt ML. Hemodynamic determinants of the timecourse of fall in canine left ventricular pressure. J Clin Invest 1976;58:751-760.
27. Sarnoff SJ, Berglund E. Ventricular function. I. Starling's law of the heart studied by means of simultaneous right and left ventricular function curves in the dog. Circulation 1954;9:706-718.
28. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997;45:1559-1565.
29. Fiordaliso F, Bianchi R, Staszewsky L, Cuccovillo I, Doni M, Laragione T, Salio M, Savino C, Melucci S, Santangelo F, Scanziani E, Masson S, Ghezzi P, Latini R. Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 2004;37:959-968.
30. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, Cox AJ, Thai K, Krum H, Gilbert RE. Inhibition of protein kinase C2 by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2009;2:129-137.
31. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003;93:246-253.
32. Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, Kelly DJ, Krum H. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 2008;294:H1804-H1814.
33. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 2002;90:135-142.
34. Woodcock EA, Wang BH, Arthur JF, Lennard A, Matkovich SJ, Du XJ, Brown JH, Hannan RD. Inositol polyphosphate 1-phosphatase is a novel antihypertrophic factor. J Biol Chem 2002;277:22734-22742.
35. Boyle AJ, Kelly DJ, Zhang Y, Cox AJ, Gow RM, Way K, Itescu S, Krum H, Gilbert RE. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol 2005;39:213-221.
36. Lim H, Zhu YZ. Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci 2006;63:2584-2596.
37. Clark JE, Sarafraz N, Marber MS. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol Ther 2007;116:192-206.
38. Qin F, Shite J, Liang CS. Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: association with changes in MAPK pathways. Am J Physiol Heart Circ Physiol 2003;285:H822-H232.
39. Ruwhof C, van der Laarse A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 2000;47:23-37.
40. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 2005;289:H501-H512.
41. Maurer MS, Spevack D, Burkhoff D, Kronzon I. Diastolic dysfunction: can it be diagnosed by Doppler echocardiography? J Am Coll Cardiol 2004;44:1543-1549.
42. Bronzwaer JG, Paulus WJ. Matrix, cytoskeleton, or myofilaments: which one to blame for diastolic left ventricular dysfunction? Prog Cardiovasc Dis 2005;47: 276-284.
43. Stefanidis A, Bousboulas S, Kalafatis J, Baroutsi K, Margos P, Komninos K, Pappas S, Papasteriadis E. Left ventricular anatomical and functional changes with ageing in type 2 diabetic adults. Eur J Echocardiogr 2009;10:647-653.
44. Chatterjee K, Massie B. Systolic and diastolic heart failure: differences and similarities. J Card Fail 2007;13:569-576.
45. Konstam MA. 'Systolic and diastolic dysfunction' in heart failure? Time for a new paradigm. J Card Fail 2003;9:1-3.
46. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-262.
47. Borbely A, Papp Z, Edes I, Paulus WJ. Molecular determinants of heart failure with normal left ventricular ejection fraction. Pharmacol Rep 2009;61:139-145.
48. Factor SM, Bhan R, Minase T,Wolinsky H, Sonnenblick EH. Hypertensive-diabetic cardiomyopathy in the rat: an experimental model of human disease. Am J Pathol 1981;102:219-228.
49. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-e181.